News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
Nordic Nanovector Release: Updated Results From Phase I/II Trial Of Betalutin In NHL Accepted For Presentation At The International Conference On Malignant Lymphoma In June 4/28/2017
TG Therapeutics (TGTX) Announces Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The American Academy of Neurology 4/28/2017
Flexion (FLXN) Highlights Two Clinical Data Presentations At The Osteoarthritis Research Society International 2017 World Congress 4/28/2017
Neurotrope To Release Results From Phase II Clinical Trial In Moderate To Severe Alzheimer’s Disease On May 1, 2017 4/28/2017
Aspyrian Therapeutics Announces The Presentation Of Clinical Data Of Its Investigational Therapy Rm-1929 Demonstrating Significant Anti-Cancer Response In Recurrent Head And Neck Cancer Patients Who Have Failed All Existing Treatment Options 4/28/2017
Braeburn Pharma Achieves Primary Endpoint In Pivotal Phase II/III Study Of BB0817, Risperidone 6-Month Implant For Treatment Of Schizophrenia 4/27/2017
Pfizer (PFE)’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation From FDA For ALK-Positive Metastatic Non-Small Cell Lung Cancer 4/27/2017
Bonti Announces Inaugural Presentation Of Phase IIa Clinical Data For Its Lead Product EB-001 4/27/2017
Syndax Announces Expansion Of Immuno-Oncology Collaboration Evaluating Entinostat In Combination With KEYTRUDA (Pembrolizumab) For The Treatment Of Colorectal Cancer 4/27/2017
Akari Therapeutics Announces Edison’s Withdrawal Of Edison Report Titled “Akari’s Coversin Matches Soliris In Phase II” 4/27/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma 4/27/2017
Gilead (GILD)'s $600 Million NASH Deal Finally Bears Fruit 4/26/2017
Powered By CIRM Grant, jCyte Launches New Clinical Trial 4/26/2017
Ra Pharma (RARX) Initiates Dosing Of RA101495 In PNH Patients 4/26/2017
Asterias Biotherapeutics Announces Publication Of Positive Phase II Data On AST-VAC1 For The Treatment Of Acute Myeloid Leukemia (AML) In 'Cancer' 4/26/2017
ARCA biopharma Announces 200th Patient Randomized Into The GENETIC-AF Seamless Design Phase IIB/III Clinical Trial 4/26/2017
New Data At American Academy of Neurology Reinforce Clinical Benefit Of Genentech (RHHBY)'s OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis 4/26/2017
FDA Clears Flex's FLX-787 To Commence U.S. Phase II Trial In ALS Under IND 4/26/2017
Galapagos (GLPG.BR) Announces New Phase II Proof-Of-Concept Study With Filgotinib In Cutaneous Lupus Erythematosus 4/26/2017
Wilson Therapeutics Presents Promising Neurological Phase 2 Data For WTX101 At American Academy of Neurology Meeting 4/26/2017
Galapagos (GLPG.BR) Announces New Phase II Proof-Of-Concept Study With Filgotinib In Cutaneous Lupus Erythematosus 4/26/2017
Finally! Novartis AG (NVS) To Release Long-Awaited Juliet CAR-T Data In June 4/25/2017
Blueberry Therapeutics Commence Phase I/II Clinical Trial Of Lead Product BB2603 4/25/2017
Capricor Therapeutics, Inc. Announces Positive Six-Month Results From The Randomized Phase I/II HOPE Clinical Trial In Duchenne Muscular Dystrophy 4/25/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase II/III EXPRESS Study Of Xyrem In Pediatric Patients With Narcolepsy With Cataplexy 4/25/2017
Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation Of Scistar Phase I/IIa Clinical Trial Of AST-OPC1 For Cervical Spinal Cord Injury 4/25/2017
Vyome Completes Enrollment For Proof Of Concept Clinical Study Of VB 1953 In Patients With Moderate To Severe Acne 4/25/2017
Eight Data Presentations At ECCMID Showcase The Broad Applicability Of SCYNEXIS, Inc. (SCYX)’ Lead Anti-Infective Candidate SCY-078 4/25/2017
Kalytera Therapeutics Identifies Sites For Planned Gvhd Clinical Trials; Company’s Research Gains Support At EBMT 2017 4/25/2017
Epizyme (EPZM) Announces Tazemetostat Fast Track Designation For Follicular Lymphoma And Plenary Session On Phase II NHL Data At ICML 4/25/2017
ASLAN Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval Of Opdivo (Nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer 4/24/2017
Medivir (MVRBF) Release: Update On The Development Of Simeprevir As Part Of The Triple Combination With AL-335 And Odalasvir (JNJ-4178) 4/24/2017
Mologen (MOLGF.PK): Positive Subgroup Results Of The Exploratory Phase II IMPULSE Study Of Lefitolimod In Extensive-Disease Small-Cell Lung Cancer (SCLC) 4/24/2017
Merck & Co. (MRK) Announces New Phase II Data On Investigational Triple Combination Therapy MK-3682B For Chronic Hepatitis C 4/24/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection 4/24/2017
Achillion (ACHN) Announces Additional Phase II Results Including 100% SVR24 For Genotype 1 HCV After 6-Weeks Of Once Daily JNJ-4178 4/24/2017
Arbutus Biopharma (ABUS) Announces ARB-1467 Data Presentation At EASL4/24/2017
Akari Therapeutics Demonstrates Positive Response With Coversin In Ongoing Phase II PNH Trial And In Additional Clinical Targets 4/24/2017
Vaccinex, Inc. Announces Preliminary Data From The SIGNAL Clinical Trial (Investigational Drug VX15/2503 As A Potential Treatment For Huntington’s Disease) 4/24/2017
Bristol-Myers Squibb (BMY)'s NASH Candidate Hits Main Goals In Mid-Stage Study 4/24/2017
Inovio Pharma (INO) Initiates Phase II Efficacy Trial With VGX-3100 For HPV-Related Vulvar Pre-Cancers 4/24/2017
aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At The American Academy of Neurology 69th Annual Meeting 4/24/2017
XOMA  (XOMA) Announces Positive Results From Its Phase II Proof-Of-Concept Study Of Prolactin Inhibition 4/24/2017
Wilson Therapeutics Presented Positive Final Phase II Data For WTX101 At EASL Annual Meeting 4/24/2017
aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy 4/24/2017
aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting 4/24/2017
Data Enhances Understanding Of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) And CRV431 4/24/2017
Tiziana Life Sciences Plc Announces Approval Of A Phase II Clinical Trial Protocol For Milciclib In Patients With Hepatocellular Carcinoma 4/24/2017
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial 4/24/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In The BEKINDA Phase II Study For IBS-D 4/24/2017
Pfizer (PFE) Receives Positive CHMP Opinion For BESPONSA (Inotuzumab Ozogamicin) For The Treatment Of Relapsed Or Refractory Acute Lymphoblastic Leukemia 4/21/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection 4/21/2017
Aldeyra (ALDX) Receives Orphan Drug Designation From FDA For ADX-102 In Sjögren-Larsson Syndrome 4/21/2017
Gilead (GILD) Presents Proof-Of-Concept Data For GS-0976 In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017 4/21/2017
Aurinia (AUPH) Releases Additional 48-Week Data From The AURA-LV Study During Late-Breaking Session At National Kidney Foundation 2017 Spring Clinical Meetings 4/21/2017
Eiger Biopharma Announces Additional Phase II Clinical Trial Results For Lonafarnib At The International Liver Congress 2017 4/21/2017
BeiGene (BGNE) Announces Initiation Of First Pivotal Study In China Of PD-1 Antibody BGB-A317 4/21/2017
Jounce (JNCE) Initiates Phase II Portion Of ICONIC Study Of JTX-2011 In Patients With Advanced Solid Tumors 4/21/2017
Why Former Medivation (MDVN) CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant (AXON) 4/20/2017
Novartis AG (NVS) Remains Hush-Hush About CAR-T Trial But the FDA is Impressed and Thinks It's a Breakthrough 4/20/2017
NIH Study In The New England Journal of Medicine Shows Novartis AG (NVS) Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017
Phase I/II Clinical Trial Of Agenus (AGEN)' Anti-PD-1 Antibody Begins 4/20/2017
Can Psoriatic Arthritis Lift Gilead (GILD)'s Sinking Ship? 4/20/2017
BioPharmX Completes Last Subject Visit In Its Phase IIb Trial Of BPX-01, Expects To Report Topline Results First Half Of May 2017 4/20/2017
Gilead (GILD) To Present Clinical And Preclinical Data On Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017 4/20/2017
Lysogene Announces Selection Of MRI Interventions (MRIC)’ Smartflow Cannula For Phase II/III Clinical Study In MPS IIIA 4/20/2017
Arrowhead Pharma (ARWR) Presents ARC-520 And ARC-521 Clinical Data At The International Liver Congress 4/20/2017
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase II Combination Trial Of PROSTVAC, Ipilimumab And Nivolumab In Patients With Localized Prostate Cancer 4/19/2017
Laurent Receives FDA And Health Canada Clearance To Initiate APPLAUD Phase II Clinical Study Of LAU-7b For The Treatment Of Cystic Fibrosis 4/19/2017
RedHill Biopharma (RDHL) To Host R&D Day On BEKINDA For Acute Gastroenteritis And IBS-D 4/19/2017
Vical  (VICL) Completes Target Enrollment In Its Phase II Therapeutic HSV-2 Vaccine Trial 4/19/2017
Flex Presents Human Efficacy Data On FLX-787 At American Academy of Neurology Annual Meeting 4/19/2017
GeNeuro Initiates Phase IIa Study With Gnbac1 In Type 1 Diabetes In Australia 4/19/2017
This Year’s Superbug Norovirus Sickens Hundreds of Millions, Prompting Urgent Race for Vaccine 4/18/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study 4/18/2017
Antibe Therapeutics (ATE.V) Provides Update On Clinical Development Program For Its Lead Drug, ATB-346 4/18/2017
NLS Pharma Announces Completion Of Phase II Study For NLS-1, Its Lead ADHD Compound; New Investors, New Patents 4/18/2017
Shionogi Presents New Data On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188 A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza At ECCMID 2017 4/18/2017
FDA Confirms ProMetic BioSciences, Inc.'s PBI-4050 IPF Clinical Trial Design 4/18/2017
Sucampo (SCMP) Release: New Study Published In PLOS ONE Advances Science Around VTS-270 For Treatment Of Niemann-Pick Disease Type C1 4/18/2017
Circassia (CIR.L) Finally Throws In The Towel On Allergy Program After Trial Failures 4/18/2017
Mateon Therapeutics (MATN) Announces Encouraging Results From First Interim Analysis Of Phase II/III FOCUS Study In Platinum-Resistant Ovarian Cancer 4/18/2017
Aldeyra (ALDX) Announces Last Patient Dosed In Allergic Conjunctivitis Phase IIb Clinical Trial 4/18/2017
Potential For CytoDyn (CYDY)’s PRO 140 For Treating HIV Patients Deemed Too Broad For Orphan Drug Designation By The FDA 4/17/2017
Cidara (CDTX) To Present Data On Novel Antifungal CD101 And Cloudbreak Antibacterial Immunotherapy At ECCMID And SID Annual Meetings 4/17/2017
The Medicines Company (MDCO) To Present Data At ECCMID 2017 On Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam 4/17/2017
AmpliPhi Bio (APHB) Announces Positive Feedback From FDA On Phase II Development Proposal 4/17/2017
CASI Pharma (CASI) Reports On Enrollment Status Of ENMD-2076 Phase II Study In Triple-Negative Breast Cancer 4/14/2017
FDA Allows NuvOx Pharma To Run A Phase II Clinical Trial In Brain Cancer 4/13/2017
Relmada Therapeutics Announces FDA Fast Track Designation For D-Methadone For Adjunctive Treatment Of Major Depressive Disorder 4/13/2017
AOBiome Completes Patient Enrollment In Phase II Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure 4/13/2017
AcelRx (ACRX) Reports Publication Of Manuscripts Analyzing IV, Transdermal And Sublingual Patient-Controlled Analgesia Systems 4/13/2017
Immunitor Release: Key Capital Announces Terminal Liver Cancer Trial Results Publication 4/13/2017
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Results From Phase II Clinical Trial Of Alidornase Alfa (AIR Dnase) For The Treatment Of Cystic Fibrosis 4/12/2017
Biocryst (BCRX) Expands Development Of BCX7353 To Explore Treatment Of Acute HAE Attacks 4/12/2017
Novan Reports Positive Topline Results With SB208 In Phase II Trial 4/12/2017
Argenx Launches Phase II Study Of ARGX-110 As A Monotherapy In Relapsed/Refractory CTCL Patients 4/12/2017
TRANSGENE (ENX:TNG) And Institut Bergonié Start The Phase II Part Of METROmaJX Trial 4/12/2017
Kadmon Announces Publication Of Clinical Data Showing KD025 Improved Clinical Scores In Psoriasis Patients 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Inotek (ITEK) Completes Patient Recruitment In Phase II Trial Of A Fixed-Dose Combination (FDC) Of Trabodenoson And Latanoprost 4/11/2017
Windtree Therapeutics (WINT) Announces Successful Completion Of Second And Final AEROSURF Phase IIb Clinical Trial Interim Safety Review 4/11/2017
Rebiotix Reports Positive Top Line Data From Open-Label Phase II Trial Of RBX2660 In Recurrent Clostridium Difficile 4/11/2017
Renova Therapeutics Release: Human Gene Therapy Publishes Review Of Randomized Clinical Trials Of Gene Transfer For Heart Failure With Reduced Ejection Fraction 4/11/2017
Key Milestone Reached In Catalyst Biosciences’s Subcutaneous Factor IX Program 4/11/2017
AzurRx Provides Update On MS1819 Phase II Trial 4/11/2017
Ohr Pharma (OHRP) Provides Update On Ongoing Squalamine Clinical Trial In Wet-AMD 4/11/2017
Five Prime (FPRX) Announces Completion Of Enrollment For The Phase II Part Of The Ongoing Trial Of Cabiralizumab For The Treatment Of Pigmented Villonodular Synovitis (PVNS) 4/11/2017
Repros Therapeutics (RPRX) Release: Company Holds Meeting With FDA To Discuss Oral Proellex In The Treatment Of Uterine Fibroids 4/10/2017
Bay Area's Geron (GERN) Survives for Now, But Johnson & Johnson (JNJ) Still Reserves the Right to Bolt on Imetelstat 4/10/2017
Inventiva Hits Clinical Milestone With Enrollment Of 100th Patient In IVA337 Phase IIb FASST Trial In Systemic Sclerosis (SSc) 4/10/2017
Anthera Announces Completion Of Dosing In The Phase II BRIGHT-SC Study Of Blisibimod In Patients With IgA Nephropathy 4/10/2017
Cellceutix (CTIX) CEO Discusses Brilacidin Following Interim Trial Results For Treating Oral Mucositis And Inflammatory Bowel Disease 4/10/2017
OncoMed (OMED)’s Phase II Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint 4/10/2017
FDA Calls Regeneron (REGN)'s Evinacumab a Breakthrough 4/7/2017
Medivir (MVRBF) Announces Positive Data From The Phase II Study Of Remetinostat In Patients With Early-Stage Cutaneous T-Cell Lymphoma 4/7/2017
Probiodrug AG Release: Last Patient Last Visit (LPLV) Reached In The SAPHIR Study 4/7/2017
Zavante Therapeutics' ZOLYD Met Primary Endpoint In Pivotal ZEUS Study For Treatment Of Complicated Urinary Tract Infections 4/6/2017
Despite a Mixed PhII, Allergan (AGN) Charges Toward a Late-Stage Depression Study for Botox 4/6/2017
Innocrin Appoints Fred Eshelman, Pharmd As CEO And Is Granted Fast Track Designation By FDA For Seviteronel Treatment Of Women With Triple-Negative Breast Cancer And Women Or Men With Estrogen Receptor-Positive Breast Cancer 4/6/2017
Achillion (ACHN) Announces Initiation Of Patient Dosing In Phase II Study Of ACH-4471 For Paroxysmal Nocturnal Hemoglobinuria 4/6/2017
Immunomedics (IMMU) Catches a Break With Positive Mid-Stage Lung Cancer Data 4/5/2017
Spyryx Biosciences Presents Data And Corporate Update At Two Recent Conferences In Support Of Clinical Candidate For Cystic Fibrosis 4/5/2017
Oncolytics Biotech (ONC.TO)’s REOLYSIN More Than Doubles Overall Survival in Patients With Mutated p53 Metastatic Breast Cancer 4/5/2017
MediGene AG (MDGEF.PK): Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 4/5/2017
DelMar Pharma Provides VAL-083 Updates From The Ongoing AACR Annual Meeting 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
This Little-Known $12 Billion SoCal Startup Wants to Cure Baldness and Smooth Out Your Wrinkles 4/4/2017
4 Drug Stocks With Major FDA Decisions Coming This Month 4/4/2017
NewLink Genetics (NLNK) Release: Interim Phase II Data Demonstrate Robust Response Rate With Indoximod In Combination With Keytruda® (Pembrolizumab) For Patients With Advanced Melanoma At AACR Plenary 4/4/2017
AbbVie (ABBV) Announces Ibrutinib (IMBRUVICA) Supplemental New Drug Application For Previously Treated Chronic Graft-Versus-Host-Disease (Cgvhd) Accepted For Review By U.S. FDA 4/4/2017
Neuraltus Pharmaceuticals, Inc. Release: Retrospective Analysis Finds Amyotrophic Lateral Sclerosis Patients With High Serum C-Reactive Protein (CRP) Levels May Respond To Immune Regulators Like NP001 4/4/2017
Syros Pharma Presents Data At AACR Further Supporting Clinical Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, For Genomically Defined AML And MDS Patients 4/4/2017
Amgen (AMGN) Submits Applications In The US And Europe To Expand Current Indication For XGEVA (Denosumab) To Include Patients With Multiple Myeloma 4/4/2017
Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy 4/4/2017
XBiotech (XBIT) Reports Top-Line Results For 514G3 Antibody Therapy In Serious Staphylococcus Aureus Infections 4/4/2017
Journal Of Diabetes Science And Technology Publishes Scientific Paper Authored By Oramed (ORMP) Scientists 4/4/2017
ERYtech Pharma Announces Launch Of Investigator-Initiated Phase II Study Of Eryaspase (GRASPA) For ALL 4/4/2017
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion Of Recruitment For Phase IIb Clinical Trials Of Myrcludex B In Chronic Hepatitis Delta 4/4/2017
ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg) 4/4/2017
Galapagos (GLPG.BR) Announces Three New Phase II Proof-Of-Concept Studies With Filgotinib 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
Phase II Data Show Bayer (BAY)'s Investigational Compound Copanlisib Achieved Durable Tumor Response In Indolent Non-Hodgkin's Lymphoma 4/3/2017
Oncolytics Biotech Inc. (ONC.TO)'s REOLYSIN Provides Statistically Significant Improvement In Overall Survival In Canadian Cancer Trials Group Sponsored Randomized Phase II Study In Metastatic Breast Cancer 4/3/2017
Amgen (AMGN) And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) 4/3/2017
Ascendis Showcases New Data On Rare Disease Product Pipeline At ENDO 2017 4/3/2017
Madrigal Reports 2016 Fourth Quarter And Year-End Financial Results, Reviews Key Corporate Achievements And Provides Update On Lead Clinical-Stage Compound, MGL-3196 4/3/2017
Audentes (BOLD) Announces FDA Clearance Of Investigational New Drug Application For AT132 To Treat X-Linked Myotubular Myopathy 4/3/2017
Puma Biotech (PBYI) Presents Results From The Phase II SUMMIT Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer At The 2017 AACR Annual Meeting 4/3/2017
Opthea Reports Positive Phase I/IIA Clinical Results For OPT-302 In Wet AMD 4/3/2017
Genexine Co. Ltd. Releases Positive Interim Phase II Clinical Data From PGHD Trial With Long-Acting Growth Hormone, GX-H9 At ENDO 2017 4/3/2017
Millendo Therapeutics Announces Publication Of Positive Phase II Data For MLE4901 For The Treatment Of Vasomotor Symptoms 4/3/2017
OncoMed (OMED) Presents Preclinical Data For Anti-TIGIT Program At The AACR Annual Meeting 2017 4/3/2017
Massachusetts General Hospital/Dana Farber Initiate Expansion Of ONC201 Glioblastoma Trial 4/3/2017
Caladrius Biosciences (CLBS) Announces Addition Of Four Clinical Sites, Including Joslin Diabetes Center, For The Ongoing Phase II Study Of CLBS03 In T1D 4/3/2017
Halozyme (HALO) Crashed After Enrollment In Early Clinical Trials Have Been Temporarily Suspended 3/31/2017
Johnson & Johnson (JNJ) Stops Mid-Stage Trial For Genmab A/S (GEN.CO)'s Blood Cancer Drug Due To Futility 3/31/2017
NovoCure Enrolls Last Patient In STELLAR Trial Testing Tumor Treating Fields In Combination With Standard Of Care Chemotherapy In Mesothelioma 3/31/2017
Akari Therapeutics Announces FDA Fast Track Designation For Coversin 3/31/2017
Opthea Conference Call/Webcast -- Update On OPT-302 Phase 1/2A Wet AMD Clinical Trial 3/31/2017
Tiny Massachusetts Phenom Corbus (CRBP) Plunges Despite Reporting Positive Phase II CF Data 3/30/2017
Ignyta (RXDX) Announces Peer-Reviewed Publication Of Activity Of A TRK Inhibitor In A Primary Brain Tumor: Successful Treatment Of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published In Precision Oncology 3/30/2017
Spectrum Pharma (SPPI) Announces Initiation Of A Phase II Trial Of Poziotinib In Non-Small Cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutations 3/30/2017
Akcea Therapeutics Initiates Phase 2 Study Of AKCEA-APO(A)-L Rx In Patients With High Lp(A) And Cardiovascular Disease 3/30/2017
Omeros (OMER) Reports More Positive Data In OMS721 Phase II Trial In Renal Diseases 3/30/2017
Amgen (AMGN) Release: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia 3/30/2017
Takeda (TKPYY)’s Dengue Vaccine Candidate Elicited Broad Immune Responses In Children And Adolescents Living In Dengue-Endemic Areas; Interim Phase 2 Analysis Published In The Lancet Infectious Diseases 3/30/2017
Avillion Signs Clinical Co-Development Agreement With Merck & Co. (MRK) To Advance Anti IL-17 A/F Nanobody In Psoriasis 3/30/2017
After Much Anticipation, Cellectar Biosciences  (CLRB) Initiates NCI-Supported Phase II Trial Of CLR 131 In Multiple Myeloma And Other Blood Cancers 3/30/2017
Araclon Biotech Selects MedAvante Virgil Platform For Phase II Alzheimer's Trial 3/30/2017
Progenics (PGNX) Announces Positive Topline Results From Registrational Phase IIb Trial Of AZEDRA 3/30/2017
Progenics (PGNX) Announces Positive Topline Results From Registrational Phase IIb Trial Of AZEDRA 3/30/2017
Acorda (ACOR) Announces Long-Term Safety Data For CVT-301 3/29/2017
BAVENCIO (Avelumab) Approved For The Treatment Of Metastatic Merkel Cell Carcinoma, Available For Order At BioLogics 3/29/2017
Tiny SoCal Pharma Ritter Pharma Hails A Mid-Stage Victory After Changing The Primary Endpoint And Recalculating Data Of Lactose Intolerance Drug 3/29/2017
Positive Results Of Phase IIb Clinical Trial Of Pharmalink AB's Nefecon In Primary IgA Nephropathy Published In The Lancet 3/29/2017
A Look at Biogen (BIIB)'s Big Bet on the Holy Grail of Science—Alzheimer's 3/29/2017
Questions Arise Over the World's Richest Doctor's 'Breakthrough' Cancer Therapy Promo Videos 3/28/2017
CureLab, Inc. Publishes Results Of Phase I/IIa Clinical Trials Of Its Anti-Cancer DNA Vaccine, Elenagen 3/28/2017
Clementia Release: Phase II Part A Open Label Extension Trial Of Palovarotene For Treatment Of Patients With Fibrodysplasia Ossificans Progressiva Continues Positive Trends 3/28/2017
Millendo Therapeutics Announces Initiation Of Phase II Clinical Trial Of ATR-101 In Patients With Endogenous Cushing’s Syndrome 3/28/2017
Akebia (AKBA) Announces Publication Of Phase IIa Results For Vadadustat In Patients With Anemia Related To Chronic Kidney Disease 3/28/2017
RXi Pharma (RXII) Granted Patent In Japan For Lead Clinical Candidate RXI-109 3/28/2017
Replicel Life Sciences's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs Of Healing Chronic Tendon Problems 3/28/2017
Akervall Technologies Awarded Highly Competitive National Science Foundation Phase IIB SBIR Grant 3/28/2017
Oncoceutics Release: ONC201 Phase I Trial Results Reported In Clinical Cancer Research 3/28/2017
Lysogene Announces Baseline Data From First International Pivotal Observational Study In MPS IIIA 3/28/2017
How This New Jersey Biotech is Taking on Amgen (AMGN) 3/27/2017
Infectex Announces Positive Phase IIb-III Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis 3/27/2017
Aurinia (AUPH) Highlights 48-Week Data From Open-Label AURION Study At 12th International Congress On SLE (LUPUS 2017) & The 7th Asian Congress On Autoimmunity (ACA 2017) 3/27/2017
Newron Pharma (NWRN) Presents Encouraging Detailed Results Of Its Phase IIa Study With Evenamide In Patients With Schizophrenia 3/27/2017
Biothera’s Phase II Study Of Imprime PGG Combination Therapy In Non-Small Cell Lung Cancer Patients Published In Investigational New Drugs 3/27/2017
Generex Biotechnology Corporation (GNBT) Announces Featured Presentation Of Cancer Immunotherapy Developed By Subsidiary At OPT Boston 3/27/2017
Omeros (OMER) To Present Results From Dose-Ranging Stage Of OMS721 Clinical Trial In Atypical Hemolytic Uremic Syndrome At World Congress Of Nephrology 3/27/2017
ERYtech Pharma Reports Positive Phase IIb Data For Eryaspase For The Treatment Of Metastatic Pancreatic Cancer 3/27/2017
Neuren Pharma’s Phase II Trial Of Trofinetide Demonstrates Significant Clinical Benefit In Pediatric Rett Syndrome 3/27/2017
Asana Biosciences Highlights Progress In Its Oncology Portfolio With New Data At AACR 2017 On ASN002 (SYK/JAK Inhibitor), ASN003 (BRAF/PI3K Inhibitor) And ASN004 (5T4-Targeted Antibody Drug Conjugate) 3/27/2017